Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.
about
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published LiteratureHLA Haplotype Mismatch Transplants and Posttransplant CyclophosphamideThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraHaploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectivesPost-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantationImpact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantImpact of Donor-Specific anti-HLA Antibodies and Donor KIR Characteristics in Haploidentical HSCT for Beta-Thalassemia.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Haploidentical Bone Marrow Transplantation in 2015 and Beyond.High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Allogeneic stem cell transplantation for sickle cell disease.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors.Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.Case of relentless chronic phase of chronic myeloid leukaemia.Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies.Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML.T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.
P2860
Q26748867-4B9ED31A-7F50-420E-9956-65AEE35E284AQ26749454-52A26320-33F5-471D-8C87-BFBF9D516AEBQ26752908-34E79428-D33E-49FA-98C4-FAECFD3EA2ABQ28072397-6FFF4C5C-B758-400E-8383-83C6A6FB21FCQ28080452-49697349-5A75-464C-A5E5-6A21D4D0413AQ33764825-38519687-1F5A-4537-9FD6-A712E4EDC1DDQ36687119-9E2C7403-8E1C-4649-8F31-131053594B23Q36724916-EF8FB955-7559-427F-BD6A-40355EBE70C9Q37029856-75B9806F-7B9A-492D-B215-6E63BBDB0491Q37590606-D515E54F-58DF-40E3-8B70-75C4FF258716Q37618840-B0052740-AD78-447E-873D-D8202AE7008BQ37677242-067D2D52-3CA6-4EB0-84D2-4CC64937F451Q38603384-EF0BD352-3FF1-4450-A0CE-79664D8A34B1Q38607242-236F2088-51AF-4B2B-BFEC-CDB7B08B68DDQ38809840-8AB0D97D-71B0-4BD0-B8C9-3FA128B5A951Q38816505-ECC43832-A5E3-4747-83BE-DAF127A92382Q38920191-51AF5F5F-C374-45B8-97AD-D958C70811FBQ39307476-92DA91D3-2744-4E5C-A743-DCA278839B4EQ41138074-6F951FC6-B98A-4A82-89ED-8CF9C89008E7Q45795174-A740FCB7-B14C-492B-8034-57A883D17DAFQ47286422-B12FF14D-6EF8-4567-98DB-E6A0B995E4C4Q48192483-9541CF3A-B202-4347-8939-22AB76950380Q49790702-ED32A4F0-36B4-4510-8224-21D7F03E7842Q50042370-7C67C3DE-C49F-47EB-8124-40F2F0CB00ABQ51686970-78060A27-C387-4046-9146-09656BD89613Q52770387-FC1B1278-06EA-4013-B4A2-5313E588B887Q53837722-39BBF934-09F8-4D43-A39C-C607795DAACBQ54718917-07331196-0372-4725-8565-BCA01B72060FQ55060181-84733B67-12EF-44CA-AFDE-A148EA839F06
P2860
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Unmanipulated haploidentical b ...... ative conditioning: an update.
@en
type
label
Unmanipulated haploidentical b ...... ative conditioning: an update.
@en
prefLabel
Unmanipulated haploidentical b ...... ative conditioning: an update.
@en
P2093
P2860
P50
P356
P1476
Unmanipulated haploidentical b ...... ative conditioning: an update.
@en
P2093
A Bacigalupo
A M Raiola
C Di Grazia
M T Van Lint
S Luchetti
P2860
P2888
P356
10.1038/BMT.2015.93
P407
P478
50 Suppl 2
P577
2015-06-01T00:00:00Z
P6179
1036456897